Faofa ag GLP1

exenatide (ainmneacha branda Byetta and Bydureon, arna monarú ag AstraZeneca), formheasta in 2005/2012

liraglutide (Victoza le haghaidh diaibéiteas, Saxenda le haghaidh murtall, arna mhonarú ag Novo Nordisk), ceadaithe in 2010^[34]

albiglutide (Tanzeum, arna mhonarú ag GSK), ceadaithe in 2014^[35]

dulaglutide (Trulicity, arna mhonarú ag Eli Lilly), ceadaithe in 2014^[36]

lixisenatide (Lyxumia san Eoraip, Adlyxin sna Stáit Aontaithe, arna mhonarú ag Sanofi), ceadaithe i 2016^[37]

semaglutide (Ozempic agus Rybelsus le haghaidh diaibéiteas, Wegovy le haghaidh otracht, arna mhonarú ag Novo Nordisk), ceadaithe in 2017^[38]

tirzepatide (dé-GLP-1 agónaí GIP; Mounjaro do dhiaibéiteas, Zepbound le haghaidh murtall, arna mhonarú ag Eli Lilly), ceadaithe in 2022^[39]